US 10400238
Polynucleotide agents targeting complement component C5 and methods of use thereof
granted A61KA61K31/7088A61K31/712
Quick answer
US patent 10400238 (Polynucleotide agents targeting complement component C5 and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K31/7088, A61K31/712, A61K39/3955